Roche Holding AG is planning a final-stage trial of a drug that taps into a gene mutation to lower cholesterol and heart attack risk beyond what statins such as Pfizer Inc.’s $9.6 billion-selling Lipitor can do.
GlaxoSmithKline Plc’s Avandia was linked to heart attacks and other cardiovascular complications in two new studies that the authors say should prompt U.S. regulators to pull the diabetes drug from the market.
An experimental drug from Merck & Co. raised levels of good cholesterol, slashed bad cholesterol and may have helped patients avert heart complications, without the safety risks that prompted Pfizer Inc. to abandon a similar product four years ago.
AstraZeneca Plc’s Crestor failed to beat Pfizer Inc.’s Lipitor in reducing the amount of plaque in arteries, a key cause of heart disease, in a study reported just weeks before cheaper copies of Lipitor will be available.
Abbott Laboratories ’ Niaspan failed to prevent heart attacks and may have boosted stroke risk in a U.S.-funded study that calls into question the benefit of raising good cholesterol to combat the leading cause of death.